CyberKnife for Kidney Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators or your doctor for guidance.
What data supports the idea that CyberKnife for Kidney Cancer is an effective treatment?
The available research shows that CyberKnife can effectively treat kidney tumors by delivering precise radiation doses while preserving kidney function. This is based on Canada's pioneering experience with CyberKnife for primary kidney tumors, indicating its potential as a promising treatment option.12345
What safety data exists for CyberKnife treatment?
The safety of CyberKnife, also known as stereotactic body radiation therapy (SBRT), has been evaluated in various studies for different types of cancer. Studies have shown promising results in terms of local control and tolerance, particularly for prostate cancer and hepatocellular carcinoma. The treatment is considered safe and feasible, with indications increasing under strict quality assurance programs. However, there are still some uncertainties regarding the radiobiology of hypofractionation.34678
Is CyberKnife a promising treatment for kidney cancer?
What is the purpose of this trial?
CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.
Research Team
Irving D Kaplan, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Eligibility Criteria
This trial is for adults with Stage I renal cell carcinoma (kidney cancer) no larger than 8 cm, who can have a gold marker placed near the tumor and are expected to live at least another year. They must not have had other cancers in the last 2 years (except non-invasive skin cancers), be able to undergo CT/MRI scans, and use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Cyberknife Radiosurgery treatments over 3-14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CyberKnife
CyberKnife is already approved in United States, European Union, Canada for the following indications:
- Renal Cell Carcinoma
- Primary Renal Cell Carcinoma
- Localized Renal Cell Carcinoma
- Renal Cell Carcinoma
- Primary Renal Cell Carcinoma
- Localized Renal Cell Carcinoma
- Renal Cell Carcinoma
- Primary Renal Cell Carcinoma
- Localized Renal Cell Carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
Dana-Farber Cancer Institute
Collaborator